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22.2% (14/63) of patients with PNAO carried Pro379Ser or Glu875Gly in ERCC4, or, Asp425Ala, Gly446Asp or Ser797Cys in ERCC6, as compared to 8.7% (152/1,750) of unaffected patients (OR=3.0, 95% CI 1.6-5.6, P=2.5x10 -4 ).
CONCLUSIONS:
Our study provides evidence for a role of NER genes in oxaliplatin-induced peripheral neuropathy, together with mechanistic insights.
INTRODUCTION
Oxaliplatin, a third-generation platinum drug, in combination with 5-fluorouracil and leucovorin (FL), or oral capecitabine, is standard treatment for locally advanced and metastatic colorectal cancer (CRC); it improves both response and progression-free survival. 1, 2 It also improves disease-free survival in the adjuvant treatment of stage II and III colon cancer patients. 3 In addition, oxaliplatin is widely used to treat other gastrointestinal malignancies. Platinum agents exert their effects by forming interand intra-strand DNA cross-links, 4 which stall the cell cycle, inhibit DNA synthesis 5 and trigger apoptosis. 6 Oxaliplatin also induces oxidative DNA damage. 7 Peripheral neuropathy is a well-recognised dose-limiting toxicity of oxaliplatin. 8, 9 High cumulative doses are associated with chronic peripheral nerve damage causing sensory ataxia and functional impairment. 10 Chronic sensory neuropathy has been observed in around half of patients who received oxaliplatin with infusional FL. 11 Importantly, it is neurotoxicity, rather than tumour progression, which is often the cause of treatment discontinuation. 12 Since neurotoxicity is not correlated with response, 12 it is considered a potentially avoidable side effect. The underlying cause of peripheral neuropathy is not known, although oxidative stress may be a contributing factor. [13] [14] [15] Although numerous genetic associations with peripheral neuropathy have been proposed (GSTP1, [16] [17] [18] [19] AGXT, 20 ERCC1, 21 24 together with several genome-wide associated loci 25, 26 ) , none have been independently validated and introduced into patient stratification. 6 Here, we sought to delineate the underlying cause by exome resequencing patients with severe peripheral neuropathy after treatment with oxaliplatin-based chemotherapy.
MATERIALS AND METHODS

Patients
We analysed blood DNA samples from unrelated patients with advanced CRC (aCRC) from the UK national trial COIN (NCT00182715). 27 Patients were randomised to receive continuous oxaliplatin and fluoropyrimidine chemotherapy, continuous chemotherapy plus cetuximab, or intermittent chemotherapy. In all patients, treatment was identical for the first 12 weeks apart from the choice of fluoropyrimidine together with the randomisation of ± cetuximab. All patients gave fully informed consent for their samples to be used for bowel cancer research (approved by REC [04/MRE06/60]). We obtained the maximum grade of peripheral neuropathy after 12 weeks of treatment. Patients with grade 3/4 peripheral neuropathy or that had had oxaliplatin-dose reduction due to severe peripheral neuropathy were classified as suffering from peripheral neuropathy associated with oxaliplatin (PNAO). Patients with no, or grade 1, peripheral neuropathy formed a control group and were classified as not having PNAO. Patients with grade 2 peripheral neuropathy were excluded to allow a better discrimination between the two patient groups.
Molecular analyses
We excluded known inherited neuropathies by carrying out multiplex ligationdependent probe amplification analysis of PMP22 (~75% of patients with Charcot-Marie-Tooth syndrome, the most common form of inherited neuropathy, have a 
Statistical and bioinformatic analyses
For association analyses, R v.3.3.2 was used for the Pearson's Chi-squared test or Fishers exact test, where appropriate. Average survival data for oxaliplatin and UV light exposure in S.pombe was normalised to wild type and analysed using SPSS v.23 ANOVA with Dunnett correction (following transformation using the arcsine function). For DNA repair assays, statistical analyses were performed in SPSS using a two-way ANOVA, with mutation status and treatment as the independent variables.
The dependent variable was CPD quantification (ng/ml) as a measure of DNA repair.
Individual ANOVAs were run at 24 and 48 hours. In silico predictions for functional significance of nonsynonymous variants were determined using Align-Grantham Variation/Grantham Deviation (Align-GVGD). Linkage disequilibrium (LD) was obtained using Haploview v.4.2.
RESULTS
Of the 2,445 patients with aCRC in the COIN trial, 23% of those that received oxaliplatin and fluorouracil-based therapy and 16% of those that received oxaliplatin and capecitabine-based therapy had severe (≥ grade 3) peripheral neuropathy over the course of the trial. 27 We focussed on patients with severe PNAO within the first 12 weeks of treatment (Supplemental Materials and Methods and 57%, 884/1542 with response data), this was not statistically significant (P=0.14).
Nine of the 63 patients with severe PNAO had exome resequencing of their germline blood DNA samples. These patients were selected based on review of their medical notes and had no potential confounding clinical complications. We identified on average 48 (range 40-56) stop gains and 88 (73-111) indels predicted to result in frameshift mutations, per patient exome (Supplemental Table) . We excluded known inherited neuropathies in these patients by PMP22 dosage analysis and by examining the resequencing data for 66 candidate genes (no stop gains or truncating indels were predicted).
Novel truncating mutation in ERCC4
Variants not present in dbSNP v.132 (assigned as novel) were considered most likely to cause PNAO; we identified on average 8 (range 2-11) and 28 (16-57) novel stop gains and frameshifting indels, respectively, per patient (Supplemental Table) .
We also considered that germline truncating mutations in genes involved in oxaliplatin transport, metabolism or the repair of its associated damage might be responsible for PNAO; we identified 104 such genes from literature reviews (Supplemental Materials and Methods). All nine patients carried truncating variants in these selected genes (range 1-4); however, only one of these variants, in a single patient, was novel (Supplemental Table) . Patient 8 carried the novel stop gain Ser613X in the nucleotide excision repair (NER) gene ERCC4, which was confirmed by Sanger sequencing of an independent PCR product (Supplemental Table) . We did not find any other coding region variants in the second ERCC4 allele in Patient 8 after direct sequence analysis of their entire ORF and flanking intronic sequences.
Clinical review confirmed that this patient did not have xeroderma pigmentosum (XP) (caused by bi-allelic ERCC4 mutations).
We carried out a more comprehensive analysis of all known DNA repair genes (REPAIRtoire, n=163 genes, http://repairtoire.genesilico.pl/, 28 and, MD Anderson / Wood's DNA repair list, n=244 genes, https://www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repairgenes.html, 29 ), including those in the base excision repair system that repair oxidative DNA damage, 30 but did not find any further novel stop-gains or truncating indels.
Functional analysis of the ERCC4 stop mutation
We investigated whether the ERCC4 nonsense mutation induced sensitivity to oxaliplatin and UV light (causes cyclobutane pyrimidine dimers [CPDs] that are repaired by NER). We re-created the mutation in the Schizosaccharomyces pombe homolog rad16 (Ser585X) in a base strain and a strain deficient in endonuclease uve1 (a pombe-specific alternative UV light repair system). Following oxaliplatin treatment, we observed decreased survival for rad16-Ser585X (P=3.5x10 -2 ) in comparison to wild type rad16 (rad16 + ), and in a similar range to a control rad16 deleted mutant (rad16Δ) (Fig.1A) . Similarly, we observed decreased survival of uve1Δ-rad16-Ser585X following treatment with UV light (P<1x10 -3 ) (Fig.1B) .
Multiple rare ERCC4 variants associated with peripheral neuropathy
We sought further evidence for a role of ERCC4 in PNAO and Sanger sequenced the ERCC4 ORF and flanking intronic sequences in all 63 patients with PNAO. We did not find any further stop gains or truncating indels; however, we did identify four rare (minor allele frequencies <5% in dbSNP) nonsynonymous variants (Pro379Ser, rs1799802, in 3 patients; His466Gln, rs372950439, in 1 patient; Arg576Thr, rs1800068, in 1 patient; Glu875Gly, rs1800124, in 4 patients) (Table 1) . Pro379Ser, Arg576Thr and Glu875Gly were predicted to interfere with function ( Table 2) . We also identified one common nonsynonymous (Arg415Gln, rs1800067), three synonymous and three 5' untranslated region (UTR) variants. We genotyped the ERCC4 nonsynonymous variants in all COIN patients with available samples. His466Gln was not seen in any further patients. Each of the other rare variants were found more frequently in cases with, as compared to those without, PNAO ( 
Functional analysis of ERCC4 nonsynonymous variants
We sought evidence for causal effects of Pro379Ser, Arg576Thr and Glu875Gly using EBV-transformed human lymphoblastoid cell lines established from healthy individuals that carried each variant in a heterozygous state (n=3 for each variant and wild type controls). Although treatment with UV light reduced viability in all lines, we did not observe any differences between wild type and variant cell lines (data not shown). In terms of repair capacity after DNA damage with UV light, all wild type cell lines showed noticeable repair 24 hours after treatment, with the majority of CPDs being repaired by 48 hours (Fig.2) . In contrast, all three sets of variant cell lines displayed reduced repair in the initial (P<1x10 -3 at both 24 and 48hours) and validation (P<1x10 -3 at both 24 and 48hours) experiments (Fig.2) .
Validated role for NER in PNAO
We attempted to validate a role for NER gene defects in PNAO and sought novel nonsynonymous variants in all ERCC gene family members by re-analysing the exome resequencing data. We identified Gly929Arg in ERCC6 in one patient, which was confirmed using an independent PCR product. We sought further potentially causal ERCC6 variants by direct sequence analysis of the ORF, intronic boundaries and 5'UTR in all 63 patients with PNAO. We identified nine rare (Table 1 ) and five common nonsynonymous variants, two synonymous variants and one 5'UTR variant;
we genotyped nonsynonymous variants in all available cases. Seven rare nonsynonymous variants were predicted to be damaging (C55-C65), three of which (Asp425Ala, Pro694Leu and Ser797Cys) were individually overrepresented in patients with PNAO (Table 3 ). Combined, rare ERCC6 nonsynonymous variants were highly associated with peripheral neuropathy (in 20.6% [13/63] 
Combined analyses of ERCC4 and ERCC6
Since private variants may skew statistical associations, we considered only rare ERCC4 and ERCC6 nonsynonymous variants that were present in ≥2 patients with PNAO. In total, 22.2% of patients with PNAO carried Pro379Ser or Glu875Gly in ERCC4, or, Asp425Ala, Gly446Asp or Ser797Cys in ERCC6, as compared to 8.7% of unaffected patients (OR=3.0, 95% CI 1.6-5.6, P=2.5x10 -4 ) ( Table 4 ).
DISCUSSION
The rare variant hypothesis predicts that individually rare, but collectively common, inherited variants play a significant role in disease susceptibility. 32 For example, rare nonsynonymous variants in the genes encoding apolipoprotein A1, the adenosine triphosphate binding cassette transporter A1 and lecithin cholesterol acyltransferase, are over-represented in individuals with low plasma levels of high-density lipoprotein cholesterol, a major risk factor for coronary atherosclerosis. 33 Furthermore, multiple rare nonsynonymous variants in APC play a significant role in inherited predisposition to colorectal adenomas. 34 Here, after identifying a novel ERCC4 truncating mutation in a patient with PNAO, we found that multiple rare ERCC4 and ERCC6 nonsynonymous variants were over-represented in affected individuals. Therefore, the rare variant hypothesis may also be applicable to germline susceptibility to toxicity from therapy. If validated by others, the ERCC4 and ERCC6 nonsynonymous variants described herein would be considered 'moderately' penetrant risk alleles for oxaliplatin-induced peripheral neuropathy, as a proportion of carriers did not have PNAO within 12 weeks of treatment.
ERCC4 forms a complex with ERCC1, which carries out 5' incision of damaged DNA in NER, the main repair pathway involved in the removal of bulky and DNA-distorting adducts. 35 The complex has also been implicated in interstrand crosslink (ICL) repair 36 and in the repair of double strand breaks. 37 ERCC6 encodes CSB, a SWI/SNF DNA-dependent related ATPase; 38 it is recruited to areas of DNA damage following stalling of RNA polymerase II and has multiple roles including chromatin remodelling 39 and recruitment of other NER proteins. 40 Given that ERCC4 and ERCC6 are likely targets of peripheral neuropathy-associated nonsynonymous variants, thorough examination of other NER genes is warranted to determine whether they play similar roles in toxicity to oxaliplatin.
Our finding that NER genes may play a role in oxaliplatin-induced peripheral neuropathy, is supported by observations from several other studies. Firstly, patients with XPA, XPC, XPG and Cockayne syndrome related disorders (caused by biallelic ERCC mutations) suffer from peripheral neuropathy prior to treatment. 41 The majority (17/20) of our ERCC4 or ERCC6 carriers had only one locus-specific mutant allele, and, to our knowledge, none had XP or Cockayne syndrome group B, suggesting that haploinsufficiency for a mutant allele may be sufficient to induce peripheral neuropathy upon exposure to oxaliplatin. Secondly, an Ercc1 -/Δ murine model, which has reduced expression of the ERCC4-ERCC1 complex, develops accelerated spontaneous peripheral neurodegeneration with significant structural alterations of the sciatic nerves. 42 Third, in Xpa -/-and Xpc -/-mice, chronic exposure to cisplatin resulted in an accelerated accumulation of unrepaired ICLs in neuronal cells. 43 Furthermore, the augmented adduct levels in dorsal root ganglion cells of these mice coincided with an earlier onset of peripheral neuropathy-like functional disturbance of their sensory nervous system. Few predictive biomarkers for toxicity to therapy in the treatment of CRC have been independently validated. Two rare variants in DPYD have been associated with severe toxicity in patients receiving 5-FU 44 and a polymorphism in UGT-1A has been linked to a higher risk of developing irinotecan-associated neutropenia and diarrhea; 45 however, none of these biomarkers have been introduced into routine clinical practice due to their poor sensitivity and specificity. Here, we identified roles for NER gene variants in toxicity to oxaliplatin, which, if validated, may represent an opportunity for patient stratification.
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